Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Scimago
  • Ulrich's Periodicals Directory
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • MIAR
  • Scientific Indexing Services (SIS)
  • Euro Pub
  • Google Scholar
Share This Page
Journal Flyer
Flyer image
Nanotechnology in liver cancer
3rd International Conference on Nanotek & Expo
December 02-04, 2013 Hampton Inn Tropicana, Las Vegas, NV, USA

Manfred George Krukemeyer and W. Wagner

Scientific Tracks Abstracts: J Nanomed Nanotechnol

Abstract:

Therapies of liver tumors display diverse treatment alternatives. The administration of cytostatics coupled with and without iron oxides (Fe 3 O 4 ) has been presented in an experimental series with 36 animals with prior implantation of an R 1 H rhabdomyosarcoma in the liver, since iron undergoes selective phagocytosis in the liver. In group I, mitoxantrone is injected into the lateral tail vein of the animals (n=12) in a dosage of 1 mg/kg of body weight. Group III (n=12 animals) received mitoxantrone coupled with iron oxide (Fe 3 O 4 ), and Group II (n=12 animals) received NaCl, in the same dosage for all groups. In the sonography and in the measurement of the volume, a significantly smaller tumor growth is found in group ii compared with group I and III. The volume was measured manually postmortally in mm 3 (length x breadth x height). The tumor volume showed the lowest growth in group II, which was treated with mitoxantrone-coupled iron oxides. 3 animals from group II died. The autopsy revealed no indication of the cause of death. There were neither thromboses nor allergic reactions in any of the animals. It can be clearly seen that group I has a smaller mean volume and less scatter than group II. The mean of group I is also below that of group II.

Biography :

Manfred George Krukemeyer M.D., is a Doctor of medicine, lecturer of surgery, citizen of Germany, Paracelsus-Hospital Osnabrueck, Department Radio-Oncology, Germany. He did his study of Medicine from University of Vienna, Medical School, Austria, University of Kiel and University of Bonn, Medical School, Germany, 1982-1989, Department of Internal Medicine University of New York, Mount Sinai School of Medicine, USA, 1988. Priztker School of Medicine University of Illinois, Department of Abdominal and Transplant Surgery, Chicago, USA, 1988. He did his resident of surgery 1991, from University of D?sseldorf, Medical School, Humboldt University of Berlin, Medical School, Germany, Department of Surgery Raphaels Hospital M?nster, Germany, teaching hospital of University of M?nster, Medical School, Germany. He is a board approved certified Surgeon, Emergency Medicine Physician and Nutritionist. His research focuses on oncology, nanomedicine and transplantation. He has more than 50 publications in international papers, publication of 6 books, lectures about surgery and oncology in Germany, Europe, America and China, member of national and international teams of specialists in surgery and oncology